Eupraxia's EP-104GI Shows Durable Symptom Relief in Eosinophilic Esophagitis Trial — Eupraxia Pharmaceuticals Inc.

Event summary

Eupraxia's Phase 1b/2a RESOLVE trial data shows EP-104GI reduced moderate to severe odynophagia (painful swallowing) from 62% to 25% at 52 weeks.
Severe dysphagia (difficulty swallowing) dropped from 31% to 0% at 24 and 52 weeks post-treatment in Cohorts 7-9.
No treatment-emergent or procedure-related serious adverse events reported across over 130 patients and 2,000 injection sites.
Phase 2b interim data from the placebo-controlled portion of RESOLVE expected in Q4 2026.

The big picture

Eupraxia's Phase 1b/2a data for EP-104GI underscores the potential of its Diffusphere™ technology to deliver sustained symptom relief in eosinophilic esophagitis, a condition affecting over 450,000 people in the U.S. The absence of serious adverse events across multiple cohorts suggests a favorable safety profile, which could accelerate regulatory interest. If Phase 2b results confirm these findings, Eupraxia may carve out a niche in a market dominated by systemic therapies with broader side effects.

What we're watching

Clinical Efficacy: Whether the durable symptom relief observed in Phase 1b/2a translates to statistically significant results in the placebo-controlled Phase 2b trial.
Regulatory Pathway: The pace at which Eupraxia can advance EP-104GI toward pivotal trials given the positive interim data.
Market Opportunity: How Eupraxia positions Diffusphere™ technology beyond eosinophilic esophagitis into other inflammatory gastrointestinal diseases.